Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

190.51 -4.05 (-2.08%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beigene Ltd ADR

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at Upcoming Investor Conferences
From BeiGene, Ltd.
Via Business Wire
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
From BeiGene, Ltd.
Via Business Wire
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
From BeiGene, Ltd.
Via Business Wire
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
From BeiGene, Ltd.
Via Business Wire
Hang Seng Index Set For Global Expansion With Prada, XPeng, And BeiGene On The Horizon
This development comes at a time when the city is grappling with a declining market. 
Via Benzinga
Get Rich Quick With These 3 Biotech Stocks to Buy Now
The new cycle is coming your way to boost millionaire-making securities. Check out these three biotech stocks to buy. 
Via InvestorPlace
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry. 
Via InvestorPlace
JP Morgan's Bullish View On This Chinese Biotech, Says Pullback Creates Entry Point
BeiGene's JP Morgan coverage highlights upside in valuation post-pullback. Brukinsa's success and Tevimbra's potential add to the optimism. Overweight rating, $185 price target. 
Via Benzinga
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
From BeiGene, Ltd.
Via Business Wire
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
These five biotech companies could have a lot of room to run. 
Via The Motley Fool
As China's Population Declines In 2023, Will Aging Demographics Boost Healthcare Stocks?
Exploring the economic implications of China's declining population on property markets and the potential rise of healthcare and tech investments. 
Via Benzinga
3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024
Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech... 
Via Talk Markets
HBM Gets Health Boost From Drug Licensing Deals
Key Takeaways: Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech  for an initial sum of $53 million and milestone payments of up to $1.05... 
Via Benzinga
FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023
From BeiGene, Ltd.
Via Business Wire
Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem
Beijing’s BeiGene acquired global rights to a preclinical novel cyclin-dependent kinase 2 (CDK2) inhibitor from Boston’s Ensem Therapeutics in a $1.3 billion agreement. Ensem will receive an upfront... 
Via Talk Markets
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
From BeiGene, Ltd.
Via Business Wire
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma
From BeiGene, Ltd.
Via Business Wire
7 Biotech Stocks to Buy for Big-Time Gains
Biotech stocks can be big winners because they're at the forefront of scientific innovation and push the boundaries of medical research. 
Via InvestorPlace
BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present at the Jefferies London Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
Ryanair Holdings, Prime Medicine And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge... 
Via Benzinga
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash. 
Via Benzinga
Why Biophytis Shares Are Trading Higher By Over 12%: Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.